Short-term safety assessment in the use of intravenous zoledronic acid in children.

@article{Hgler2004ShorttermSA,
  title={Short-term safety assessment in the use of intravenous zoledronic acid in children.},
  author={Wolfgang H{\"o}gler and Fabian Kok-Peng Yap and David F Little and Geoffrey Ambler and Mary McQuade and Christopher T Cowell},
  journal={The Journal of pediatrics},
  year={2004},
  volume={145 5},
  pages={701-4}
}
The clinical side effects of the potent new bisphosphonate zoledronic acid in children are unknown. In this study of 34 children with various bone disorders, the frequency of postinfusion flu-like illness, hypocalcemia, and hypophosphatemia was 85%, 74%, and 82%, respectively. No renal side effects were detected after up to 3 consecutive infusions.